Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopausal Women.

NCT00145522 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.

NCT NCT00145522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopausal Women.
Lead sponsor
Solvay Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2005
Completion date
March 31, 2009
Enrollment
135 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

menopause